Latest News Feed

Press Release Aug 31, 2026
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
Press Release Aug 18, 2026
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
Press Release Aug 10, 2026
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Press Release Jul 28, 2026
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
Press Release Jul 24, 2026
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
Press Release Jul 22, 2026
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
Press Release Jul 13, 2026
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
Press Release Jul 8, 2026
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
Press Release Jul 6, 2026
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
Press Release Jun 29, 2026
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
Press Release Jun 22, 2026
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Press Release Jun 15, 2026
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
Press Release Jun 8, 2026
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
Press Release May 26, 2026
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Press Release May 18, 2026
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
Press Release May 18, 2026
Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
Press Release May 15, 2026
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
Press Release May 15, 2026
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
Press Release May 11, 2026
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
Press Release May 4, 2026
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
Press Release Apr 21, 2026
Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Press Release Apr 7, 2026
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Press Release Apr 1, 2026
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
Press Release Mar 11, 2026
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
Press Release Feb 12, 2026
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
Press Release Feb 10, 2026
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
Press Release Feb 2, 2026
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
Press Release Jan 13, 2026
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
Press Release Dec 1, 2025
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
Press Release Nov 17, 2025
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
Press Release Nov 14, 2025
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
Press Release Nov 12, 2025
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
Press Release Nov 11, 2025
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
Press Release Nov 10, 2025
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
Press Release Nov 5, 2025
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan
Press Release Nov 3, 2025
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
Press Release Oct 29, 2025
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
Press Release Oct 27, 2025
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27
Press Release Oct 22, 2025
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
Press Release Oct 20, 2025
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
Press Release Oct 15, 2025
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
Press Release Sep 30, 2025
NanoViricides, Inc. Has Filed its Annual Report

Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections
Press Release Sep 11, 2025
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

This release is being retransmitted for extra exposure to downstream sites.
Press Release Sep 9, 2025
NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
Press Release Aug 18, 2025
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
Press Release Jul 30, 2025
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
Press Release Jul 23, 2025
NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value
Press Release Jul 21, 2025
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
Press Release Jul 16, 2025
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
Press Release Jul 14, 2025
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides